Generic Product News (December 2015)

Pharmacy Times, December 2015 Heart Health, Volume 81, Issue 12

Read about the new generic products featured in December.

Dutasteride CapsulesMarketed by: Teva Pharmaceuticals USA

Compare to: Avodart (GlaxoSmithKline)

Indication: Teva Generics announced the launch of Dutasteride Capsules, the therapeutic equivalent to GlaxoSmithKline’s Avodart, in a 0.5-mg dosage strength. The product is indicated to treat symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate to reduce the risk of acute urinary retention, improve symptoms, and reduce the possibility of needing BPH-related surgery. The product is not approved to prevent prostate cancer.

Dosage Form: Capsules: 0.5 mg

For More Information: www.tevagenerics.com

Montelukast Sodium Chewable TabletsMarketed by: Camber Pharmaceuticals

Compare to: Singulair (Merck)

Indication: Camber Pharmaceuticals announced the launch of Montelukast Sodium Chewable Tablets in 4- and 5-mg tablet strengths. The drug is indicated to treat chronic asthma in adults and in children 1 year or older. The product will be available in 30- and 90-count bottles.

Dosage Form: Chewable tablets: 4 and 5 mg

For More Information: www.camberpharma.com

Aurobindo Pharma Limited

Compare to: Namenda (Forest Laboratories, Inc)

Indication: Aurobindo Pharma announced FDA approval of its Memantine Hydrochloride Tablets USP in 5- and 10-mg dosage strengths. The product is indicated to treat moderate to severe dementia of the Alzheimer’s type.

Dosage Form: Tablets: 5 and 10 mg

For More Information: www.aurobindousa.com

Levoleucovorin Calcium InjectionMarketed by: Mylan

Compare to: Fusilev (Spectrum Pharmaceuticals)

Indication: Mylan has launched Levoleucovorin Calcium Injection, the generic equivalent to Spectrum Pharmaceuticals’ Fusilev, in 10 mg (base)/mL, 175 mg (base)/17.5 mL, and 250 mg (base)/25 mL single-use vials. The product is indicated for rescue use after high-dose methotrexate therapy in osteosarcoma. It can also be used to lower toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists.

Dosage Form: Single-use vials: 10 mg (base)/mL, 175 mg (base)/17.5 mL, and 250 mg (base)/25 mL

For More Information: www.mylan.com